Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH

L. Persani, D. Preziati, C. H. Matthews, A. Sartorio, V. K K Chatterjee, P. Beck-Peccoz

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE: Serum TSH assay is a very sensitive and specific index of thyroid hormone (TH) action. Nevertheless, in particular clinical situations, such as those of inappropriate TSH secretion, the measurement of additional parameters evaluating peripheral TH action may be required in order to achieve a correct diagnosis and to assess the impact that thyroid hormone have on a given tissue. The availability of a specific RIA for serum carboxyterminal cross-linked telopeptide of type I collagen (ICTP) prompted us to study the usefulness of this specific marker of bone resorption in the differential diagnosis of thyroid disorders. DESIGN: Serum ICTP levels were measured in: (a) 10 patients with TSH-secreting pituitary adenoma (TSH-oma), (b) 40 with thyroid hormone resistance (RTH), as well as in (c) 28 patients with Graves' disease or toxic nodular goitre, (d) 31 with autoimmune primary hypothyroidism (PH) and in 8 of them during L-T4 replacement therapy, (e) 23 with central hypothyroidism (CH) during L-T4 therapy and 2 months after its withdrawal, and (f) 26 during TSH-suppressive treatment for goitre or non-metastatic differentiated thyroid cancer. Results were compared with those obtained in 2 groups of normal controls (Group A, n=61, age range: 23-68 years; Group B, n=32, age range: 6-15 years). METHODS: Serum TSH, free T4 (FT4) and free T3 (FT3) were measured by immunofluorometric assays. Serum ICTP was measured by a specific RIA with a sensitivity of 0.5 ± 0.1 μg/l, and intra- and interassay coefficients of variation lower than 6%. RESULTS: Mean values of serum ICTP levels in adult controls were 3.8 ± 1.6 (±SD) μg/l, while in pre- or peri-pubertal controls it was higher than in adults (14.4 ± 3.1 μg/l). Patients with TSH- oma showed significantly increased ICTP levels (8.7 ± 5.0 μg/l, P

Original languageEnglish
Pages (from-to)207-214
Number of pages8
JournalClinical Endocrinology
Volume47
Issue number2
Publication statusPublished - 1997

Fingerprint

Hyperpituitarism
Collagen Type I
Differential Diagnosis
Serum
Thyroid Hormones
Thyroid Hormone Resistance Syndrome
Fluoroimmunoassay
Nodular Goiter
Poisons
Graves Disease
Goiter
Pituitary Neoplasms
Bone Resorption
Hypothyroidism
Thyroid Neoplasms
Thyroid Gland
Therapeutics
Control Groups

ASJC Scopus subject areas

  • Endocrinology

Cite this

Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. / Persani, L.; Preziati, D.; Matthews, C. H.; Sartorio, A.; Chatterjee, V. K K; Beck-Peccoz, P.

In: Clinical Endocrinology, Vol. 47, No. 2, 1997, p. 207-214.

Research output: Contribution to journalArticle

@article{5ce99056bc9b4e9d8973aa12e1481a5c,
title = "Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH",
abstract = "BACKGROUND AND OBJECTIVE: Serum TSH assay is a very sensitive and specific index of thyroid hormone (TH) action. Nevertheless, in particular clinical situations, such as those of inappropriate TSH secretion, the measurement of additional parameters evaluating peripheral TH action may be required in order to achieve a correct diagnosis and to assess the impact that thyroid hormone have on a given tissue. The availability of a specific RIA for serum carboxyterminal cross-linked telopeptide of type I collagen (ICTP) prompted us to study the usefulness of this specific marker of bone resorption in the differential diagnosis of thyroid disorders. DESIGN: Serum ICTP levels were measured in: (a) 10 patients with TSH-secreting pituitary adenoma (TSH-oma), (b) 40 with thyroid hormone resistance (RTH), as well as in (c) 28 patients with Graves' disease or toxic nodular goitre, (d) 31 with autoimmune primary hypothyroidism (PH) and in 8 of them during L-T4 replacement therapy, (e) 23 with central hypothyroidism (CH) during L-T4 therapy and 2 months after its withdrawal, and (f) 26 during TSH-suppressive treatment for goitre or non-metastatic differentiated thyroid cancer. Results were compared with those obtained in 2 groups of normal controls (Group A, n=61, age range: 23-68 years; Group B, n=32, age range: 6-15 years). METHODS: Serum TSH, free T4 (FT4) and free T3 (FT3) were measured by immunofluorometric assays. Serum ICTP was measured by a specific RIA with a sensitivity of 0.5 ± 0.1 μg/l, and intra- and interassay coefficients of variation lower than 6{\%}. RESULTS: Mean values of serum ICTP levels in adult controls were 3.8 ± 1.6 (±SD) μg/l, while in pre- or peri-pubertal controls it was higher than in adults (14.4 ± 3.1 μg/l). Patients with TSH- oma showed significantly increased ICTP levels (8.7 ± 5.0 μg/l, P",
author = "L. Persani and D. Preziati and Matthews, {C. H.} and A. Sartorio and Chatterjee, {V. K K} and P. Beck-Peccoz",
year = "1997",
language = "English",
volume = "47",
pages = "207--214",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH

AU - Persani, L.

AU - Preziati, D.

AU - Matthews, C. H.

AU - Sartorio, A.

AU - Chatterjee, V. K K

AU - Beck-Peccoz, P.

PY - 1997

Y1 - 1997

N2 - BACKGROUND AND OBJECTIVE: Serum TSH assay is a very sensitive and specific index of thyroid hormone (TH) action. Nevertheless, in particular clinical situations, such as those of inappropriate TSH secretion, the measurement of additional parameters evaluating peripheral TH action may be required in order to achieve a correct diagnosis and to assess the impact that thyroid hormone have on a given tissue. The availability of a specific RIA for serum carboxyterminal cross-linked telopeptide of type I collagen (ICTP) prompted us to study the usefulness of this specific marker of bone resorption in the differential diagnosis of thyroid disorders. DESIGN: Serum ICTP levels were measured in: (a) 10 patients with TSH-secreting pituitary adenoma (TSH-oma), (b) 40 with thyroid hormone resistance (RTH), as well as in (c) 28 patients with Graves' disease or toxic nodular goitre, (d) 31 with autoimmune primary hypothyroidism (PH) and in 8 of them during L-T4 replacement therapy, (e) 23 with central hypothyroidism (CH) during L-T4 therapy and 2 months after its withdrawal, and (f) 26 during TSH-suppressive treatment for goitre or non-metastatic differentiated thyroid cancer. Results were compared with those obtained in 2 groups of normal controls (Group A, n=61, age range: 23-68 years; Group B, n=32, age range: 6-15 years). METHODS: Serum TSH, free T4 (FT4) and free T3 (FT3) were measured by immunofluorometric assays. Serum ICTP was measured by a specific RIA with a sensitivity of 0.5 ± 0.1 μg/l, and intra- and interassay coefficients of variation lower than 6%. RESULTS: Mean values of serum ICTP levels in adult controls were 3.8 ± 1.6 (±SD) μg/l, while in pre- or peri-pubertal controls it was higher than in adults (14.4 ± 3.1 μg/l). Patients with TSH- oma showed significantly increased ICTP levels (8.7 ± 5.0 μg/l, P

AB - BACKGROUND AND OBJECTIVE: Serum TSH assay is a very sensitive and specific index of thyroid hormone (TH) action. Nevertheless, in particular clinical situations, such as those of inappropriate TSH secretion, the measurement of additional parameters evaluating peripheral TH action may be required in order to achieve a correct diagnosis and to assess the impact that thyroid hormone have on a given tissue. The availability of a specific RIA for serum carboxyterminal cross-linked telopeptide of type I collagen (ICTP) prompted us to study the usefulness of this specific marker of bone resorption in the differential diagnosis of thyroid disorders. DESIGN: Serum ICTP levels were measured in: (a) 10 patients with TSH-secreting pituitary adenoma (TSH-oma), (b) 40 with thyroid hormone resistance (RTH), as well as in (c) 28 patients with Graves' disease or toxic nodular goitre, (d) 31 with autoimmune primary hypothyroidism (PH) and in 8 of them during L-T4 replacement therapy, (e) 23 with central hypothyroidism (CH) during L-T4 therapy and 2 months after its withdrawal, and (f) 26 during TSH-suppressive treatment for goitre or non-metastatic differentiated thyroid cancer. Results were compared with those obtained in 2 groups of normal controls (Group A, n=61, age range: 23-68 years; Group B, n=32, age range: 6-15 years). METHODS: Serum TSH, free T4 (FT4) and free T3 (FT3) were measured by immunofluorometric assays. Serum ICTP was measured by a specific RIA with a sensitivity of 0.5 ± 0.1 μg/l, and intra- and interassay coefficients of variation lower than 6%. RESULTS: Mean values of serum ICTP levels in adult controls were 3.8 ± 1.6 (±SD) μg/l, while in pre- or peri-pubertal controls it was higher than in adults (14.4 ± 3.1 μg/l). Patients with TSH- oma showed significantly increased ICTP levels (8.7 ± 5.0 μg/l, P

UR - http://www.scopus.com/inward/record.url?scp=0030805063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030805063&partnerID=8YFLogxK

M3 - Article

C2 - 9302396

AN - SCOPUS:0030805063

VL - 47

SP - 207

EP - 214

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -